Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neoplasms × eribulin × Clear all

Phase

Status

Completed 13 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Neoplasm Metastasis 2 Urinary Bladder Neoplasms 1 Recurrence 1 Neoplasms 1 Lymphoma 1 Inflammatory Breast Neoplasms 1 HER-2 Positive Breast Cancer 1 Adenocarcinoma 1

Interventions

Gemcitabine 29 pembrolizumab 22 Cyclophosphamide 19 Paclitaxel 17 Irinotecan 17 Carboplatin 17 Fluorouracil 16 Docetaxel 16 Capecitabine 16 Leucovorin 13 Bevacizumab 12 fludarabine 11 Oxaliplatin 11 Everolimus 11 Pemetrexed 10 Erlotinib Hydrochloride 10 Dexamethasone 10 Rituximab 9 Cisplatin 9 Blood Specimen Collection 9 venetoclax 8 Cetuximab 8 Trastuzumab 7 Nivolumab 7 Sunitinib 6 Ipilimumab 6 Epoetin Alfa 6 Bortezomib 6 Azacitidine 6 trametinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02082626 2020-03-10

ERIBULIN

University of Oklahoma

Phase 1 Terminated

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡